DE60203996D1 - Concatamere immunadhäsion - Google Patents
Concatamere immunadhäsionInfo
- Publication number
- DE60203996D1 DE60203996D1 DE60203996T DE60203996T DE60203996D1 DE 60203996 D1 DE60203996 D1 DE 60203996D1 DE 60203996 T DE60203996 T DE 60203996T DE 60203996 T DE60203996 T DE 60203996T DE 60203996 D1 DE60203996 D1 DE 60203996D1
- Authority
- DE
- Germany
- Prior art keywords
- proteins
- soluble
- dimeric
- terminus
- host cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 239000013613 expression plasmid Substances 0.000 abstract 2
- 238000003259 recombinant expression Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 102000035122 glycosylated proteins Human genes 0.000 abstract 1
- 108091005608 glycosylated proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0045028A KR100453877B1 (ko) | 2001-07-26 | 2001-07-26 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
KR2001045028 | 2001-07-26 | ||
PCT/KR2002/001427 WO2003010202A1 (en) | 2001-07-26 | 2002-07-26 | Concatameric immunoadhesion |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60203996D1 true DE60203996D1 (de) | 2005-06-09 |
DE60203996T2 DE60203996T2 (de) | 2006-01-19 |
Family
ID=36638258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60203996T Expired - Lifetime DE60203996T2 (de) | 2001-07-26 | 2002-07-26 | Concatamere immunadhäsion |
Country Status (12)
Country | Link |
---|---|
US (3) | US7229962B2 (de) |
EP (1) | EP1362062B1 (de) |
JP (1) | JP4288159B2 (de) |
KR (1) | KR100453877B1 (de) |
CN (1) | CN1293098C (de) |
AT (1) | ATE294817T1 (de) |
AU (1) | AU2002313952B2 (de) |
CA (1) | CA2429384C (de) |
DE (1) | DE60203996T2 (de) |
ES (1) | ES2239242T3 (de) |
HK (1) | HK1062305A1 (de) |
WO (1) | WO2003010202A1 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
CA2475177A1 (en) | 2002-02-11 | 2003-08-21 | Zymogenetics, Inc. | Materials and methods for preparing dimeric growth factors |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
KR100418329B1 (ko) * | 2002-07-26 | 2004-02-14 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체 |
BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP1624847B1 (de) * | 2003-05-09 | 2012-01-04 | BioGeneriX AG | Zusammensetzungen und Verfahren zur Herstellung von Glykosylierungsmutanten des menschlichen Wachstumshormons |
WO2005012484A2 (en) * | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
JP2007515410A (ja) * | 2003-12-03 | 2007-06-14 | ネオス テクノロジーズ インコーポレイテッド | GlycoPEG化卵胞刺激ホルモン |
JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのo結合型グリコシル化 |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
CA2558811A1 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
KR100545720B1 (ko) * | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
CA2891010C (en) | 2004-07-23 | 2022-09-20 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US20090292110A1 (en) * | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
WO2005021578A2 (en) | 2004-08-25 | 2005-03-10 | Amprotein Corporation | A novel chimeric polypeptide and use thereof |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
EP3061461A1 (de) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8388962B2 (en) * | 2005-04-15 | 2013-03-05 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
JP5224707B2 (ja) * | 2005-04-28 | 2013-07-03 | 持田製薬株式会社 | 抗血小板膜糖蛋白質viモノクローナル抗体 |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
JP2009502849A (ja) * | 2005-07-29 | 2009-01-29 | ラボラトワール セローノ ソシエテ アノニム | 血栓症及び癌の治療、及び/又は予防のためのacrp30の使用 |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
WO2007056812A1 (en) * | 2005-11-16 | 2007-05-24 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2007059574A1 (en) * | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US8354109B2 (en) * | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
EP2423229B1 (de) * | 2006-03-27 | 2013-05-08 | Medimmune Limited | Bindeelement für den GM-CSF-Rezeptor |
ES2385754T3 (es) | 2006-06-22 | 2012-07-31 | Novo Nordisk A/S | Receptores heterodiméricos solubles y usos de estos |
JP2009541275A (ja) * | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
JP2010512154A (ja) * | 2006-12-13 | 2010-04-22 | ズップレモル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 修飾Fcドメインを含む多量体Fc受容体ポリペプチド |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TWI432449B (zh) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | 衍生自ActRIIB的變體與其用途 |
TW201808334A (zh) | 2007-02-09 | 2018-03-16 | 艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
CA2688490C (en) | 2007-06-01 | 2022-06-21 | Scott E. Strome | Immunoglobulin constant region fc receptor binding agents |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US7968811B2 (en) * | 2007-06-29 | 2011-06-28 | Harley-Davidson Motor Company Group, Inc. | Integrated ignition and key switch |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
JP5647899B2 (ja) * | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
DK3750552T3 (da) | 2008-08-14 | 2023-07-24 | Acceleron Pharma Inc | Gdf-fælder |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
CN101747440B (zh) * | 2008-12-18 | 2014-05-07 | 嘉和生物药业有限公司 | 一种TNFR-Fc融合蛋白及其用途 |
CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ, インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ, インコーポレイテッド | 切断型ActRIIB−Fc融合タンパク質 |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
AU2010325943A1 (en) * | 2009-12-02 | 2012-06-21 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of Fc fusion proteins. |
SG182366A1 (en) * | 2010-01-05 | 2012-08-30 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
CN105820256A (zh) | 2010-07-28 | 2016-08-03 | 格利克尼克股份有限公司 | 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物 |
JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | Actriia結合剤およびその使用 |
WO2012170938A1 (en) * | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
CA2871468C (en) | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
RU2016139006A (ru) | 2014-03-05 | 2018-04-05 | Юсб Биофарма Спрл | Мультимерные fc-белки |
US20170029505A1 (en) * | 2014-04-16 | 2017-02-02 | Ucb Biopharma Sprl | Multimeric fc proteins |
MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
EP4233889A3 (de) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii-antagonisten und verwendungen davon zur behandlung von myelodysplastischem syndrom |
CN107969128A (zh) | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
AU2017279538A1 (en) | 2016-06-07 | 2019-01-03 | Gliknik Inc. | Cysteine-optimized stradomers |
CN110114460A (zh) | 2016-10-28 | 2019-08-09 | Nrl制药股份有限公司 | 乳铁蛋白/白蛋白融合蛋白质及其制备方法 |
EP3551647A4 (de) | 2016-12-09 | 2021-01-13 | Gliknik Inc. | Herstellungsoptimierung von gl-2045, einem multimerisierenden stradomer |
CA3043251A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
AU2018237682A1 (en) * | 2017-03-24 | 2019-11-14 | Orpheus Bioscience Inc. | Pantids for treatment of autoimmune disorders |
EP4219540A3 (de) | 2017-10-10 | 2023-12-06 | Alpine Immune Sciences, Inc. | Ctla-4-variante immunmodulatorische proteine und verwendungen davon |
EP3870601A4 (de) * | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | Il4/il13-rezeptormolekül zur verwendung in der veterinärmedizin |
CN115023444A (zh) | 2019-12-20 | 2022-09-06 | 再生元制药公司 | 新型il2激动剂及其使用方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US53539A (en) * | 1866-03-27 | Improvement in revolving fire-arms | ||
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
ATE309376T1 (de) | 1990-06-28 | 2005-11-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
KR100238712B1 (ko) | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
US5861151A (en) | 1991-12-20 | 1999-01-19 | Bristol-Myers Squibb Co | Soluble fusion molecules with binding specificity for cell adhesion molecules |
US6100383A (en) | 1992-01-27 | 2000-08-08 | Icos Corporation | Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions |
ZA93779B (en) | 1992-02-06 | 1993-08-05 | Schering Corp | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. |
DE4322330A1 (de) | 1992-08-31 | 1994-03-03 | Behringwerke Ag | Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
CA2123593C (en) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
WO1996031229A1 (en) | 1995-04-05 | 1996-10-10 | Beth Israel Hospital Association | Inhibiting rejection of a graft |
AU701790B2 (en) | 1995-07-17 | 1999-02-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
WO1997033617A1 (en) | 1996-03-13 | 1997-09-18 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
SE511337C2 (sv) | 1996-11-08 | 1999-09-13 | Ericsson Telefon Ab L M | Anordning för att skydda sluttransistorerna i en effektförstärkare |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
IL122818A0 (en) | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
GB9727512D0 (en) | 1997-12-31 | 1998-02-25 | Adprotech Plc | Fuzzy genes and their application in molecular adjuvants |
DE69935574T2 (de) | 1998-01-23 | 2007-12-06 | F. Hoffmann-La Roche Ag | Antikörper gegen mensliches il-12 |
US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
GB0008582D0 (en) | 2000-04-08 | 2000-05-31 | Adprotech Plc | DNA immunization vectors |
ES2298106T3 (es) | 2000-04-21 | 2008-05-16 | Conaris Research Institute Ag | Proteinas de fusion que comprenden dos moleculas gp130 solubles. |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
-
2001
- 2001-07-26 KR KR10-2001-0045028A patent/KR100453877B1/ko active IP Right Grant
-
2002
- 2002-07-26 JP JP2003515561A patent/JP4288159B2/ja not_active Expired - Lifetime
- 2002-07-26 US US10/363,427 patent/US7229962B2/en not_active Expired - Lifetime
- 2002-07-26 EP EP02753273A patent/EP1362062B1/de not_active Expired - Lifetime
- 2002-07-26 AT AT02753273T patent/ATE294817T1/de active
- 2002-07-26 CN CNB028043413A patent/CN1293098C/zh not_active Expired - Lifetime
- 2002-07-26 CA CA2429384A patent/CA2429384C/en not_active Expired - Lifetime
- 2002-07-26 DE DE60203996T patent/DE60203996T2/de not_active Expired - Lifetime
- 2002-07-26 AU AU2002313952A patent/AU2002313952B2/en not_active Expired
- 2002-07-26 ES ES02753273T patent/ES2239242T3/es not_active Expired - Lifetime
- 2002-07-26 WO PCT/KR2002/001427 patent/WO2003010202A1/en active IP Right Grant
-
2004
- 2004-05-19 HK HK04103532A patent/HK1062305A1/xx not_active IP Right Cessation
-
2007
- 2007-04-24 US US11/739,288 patent/US7670602B2/en not_active Expired - Lifetime
-
2010
- 2010-01-22 US US12/692,392 patent/US8372961B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US7670602B2 (en) | 2010-03-02 |
EP1362062B1 (de) | 2005-05-04 |
JP2004521655A (ja) | 2004-07-22 |
US20100278827A1 (en) | 2010-11-04 |
KR20030010189A (ko) | 2003-02-05 |
ES2239242T3 (es) | 2005-09-16 |
EP1362062A4 (de) | 2004-04-14 |
AU2002313952B2 (en) | 2003-11-27 |
US20030195338A1 (en) | 2003-10-16 |
KR100453877B1 (ko) | 2004-10-20 |
JP4288159B2 (ja) | 2009-07-01 |
US20090011466A1 (en) | 2009-01-08 |
HK1062305A1 (en) | 2004-10-29 |
DE60203996T2 (de) | 2006-01-19 |
CN1524092A (zh) | 2004-08-25 |
US7229962B2 (en) | 2007-06-12 |
US8372961B2 (en) | 2013-02-12 |
ATE294817T1 (de) | 2005-05-15 |
EP1362062A1 (de) | 2003-11-19 |
CA2429384A1 (en) | 2003-02-06 |
CA2429384C (en) | 2012-08-07 |
WO2003010202A1 (en) | 2003-02-06 |
CN1293098C (zh) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60203996D1 (de) | Concatamere immunadhäsion | |
US20210388047A1 (en) | Compositions and Methods of Use for Treating Metabolic Disorders | |
CN103349781B (zh) | 具有改善的药物动力学特性的修饰嵌合多肽 | |
RU2008134389A (ru) | Рекомбинантные слитые человеческие белки epo-fc с продленным временем полужизни и повышенной эритропоэтической активностью in vivo | |
TW201336865A (zh) | 免疫球蛋白Fc變體 | |
Stoyan et al. | Recombinant soluble human interleukin‐6 receptor: Expression in Escherichia coli, renaturation and purification | |
CN105477641A (zh) | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 | |
DE69633175D1 (de) | Multimere proteine | |
CY1110973T1 (el) | Βελτιωμενα διμερη sgp130fc | |
CN107428842A (zh) | 细胞因子融合蛋白 | |
Bezouska et al. | CD69 antigen of human lymphocytes is a calcium-dependent carbohydrate-binding protein | |
Tan et al. | Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility | |
NO175003B (no) | Fusjonsproteiner med eukaryotisk ballastandel, vektor som inneholder et DNA som koder for fusjonsproteinet samt E.coli celle inneholdene vektoren | |
CN108136043A (zh) | 蛋白质缀合物 | |
KR102357604B1 (ko) | 환상 펩티드를 단백질 구조에 제시시키는 초범용법 | |
WO2000047740A3 (en) | Tnf-related proteins | |
Davis et al. | Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin | |
IE912130A1 (en) | Method of treating bladder cancer cells | |
Guo et al. | Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system | |
Addi et al. | A highly versatile adaptor protein for the tethering of growth factors to gelatin-based biomaterials | |
CN102725308A (zh) | 纤连蛋白:生长因子嵌合物 | |
CA2010256C (en) | Protein anti-cancer agent | |
Pakkanen et al. | Selective expression of nonsecreted triple-helical and secreted single-chain recombinant collagen fragments in the yeast Pichia pastoris | |
Kawase et al. | Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin | |
Verrey et al. | Determinants of oligomeric structure in the chicken liver glycoprotein receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 1362062 Country of ref document: EP Representative=s name: TBK, 80336 MUENCHEN, DE |